InvestorsHub Logo

~MulaGreen~

09/29/21 8:44 AM

#10764 RE: ~MulaGreen~ #10763

In addition to surpassing the expectations from the MOE, the Company also received interest from the MOE in purchasing Escozine®, Medolife’s lead drug candidate.
The report included clinical observations made by the Company on the potential therapeutic and palliative properties of Escozine® in patients who have tested positive for the SARS-CoV-2 (COVID-19) virus, and preventative properties in hospital staff that reported zero new infections over the course of the clinical observation.
The MOE is interested in purchasing Escozine® as a preventative alternative medicine for its employees.